Latest CanVECTOR News
August 24, 2016
The Network News August edition available now

Find it on the News & Events page!

Read More

Annual incidence of

2/1000

population per year

Cost of VTE: at least

$600m

CAD a year

VTE recurrence

5-10%

per year

Chronic thromboembolic pulmonary hypertension 

3-4%

after PE

Pulmonary Embolism
leads to the hospitalization
or death of over

30,000

Canadians every year

VTE leads to significant

long-term
costs

in the form of chronic complications of VTE

Post-thrombotic syndrome

20-40%

after DVT

Adverse effects and

burden of anticoagulant therapy

Upcoming Events

Thursday, June 15, 2017 at 05:00 PM
Duration: 3 hours

CanVECTOR Investigators' Group Meeting

Friday, June 16, 2017 at 09:00 AM

SSC Meeting

Friday, June 16, 2017 at 09:00 AM

Trainee Bootcamp

Evidence Pearls on VTE

Evidence Pearls on VTE RSS Feed
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
Apr 30, 2017
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Apr 30, 2017
Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
Apr 30, 2017
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
Apr 29, 2017
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Apr 29, 2017
Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
Apr 29, 2017
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
Apr 28, 2017
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Apr 28, 2017
Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
Apr 28, 2017
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
Apr 27, 2017
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Apr 27, 2017
Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
Apr 27, 2017
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Apr 26, 2017
Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
Apr 26, 2017
Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.
Apr 26, 2017
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
Apr 26, 2017
Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.
Apr 25, 2017
External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
Apr 25, 2017
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.
Apr 25, 2017
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Apr 25, 2017

Twitter